[4K] THE BOYZ, DAY6, NCT WISH, n.SSign, CRAVITY, TNX, PURPLE KISS, TEMPEST | On the way to music bank 240322
2024-03-22
South Korea has signed agreements with global pharmaceutical companies, Johnson and Johnson's Janssen and Pfizer, to bring in COVID-19 vaccines that can immunize up to 16 million people. The vaccines from Janssen are expected to arrive by the second quarter of next year.
Prime Minister Chung Sye-kyun on Thursday announced that South Korea has signed deals to purchase COVID-19 vaccines from Johnson and Johnson's Janssen and Pfizer.
At a COVID-19 meeting with officials, Chung said the government will buy vaccines for six million people from Janssen, up from its initial plan for four million, with a goal to start vaccinations in the second quarter of next year.
While vaccines for another ten million people are expected to be brought in from Pfizer starting in the third quarter of 2021, the prime minister said negotiations are under way to push the delivery up to the second quarter.
Amid growing public criticism over the delay in securing vaccines, Chung stressed that the government will prioritize safety and effectiveness, before ensuring that immunizations begin as soon as possible.
Earlier, Seoul announced plans to secure enough vaccines to be administered to 44 million people, enough to cover around 88 percent of the population, but the increased supply from Janssen will cover 46 million.
An advance payment of 85 billion won was made to the World Health Organization’s(WHO) global vaccine project known as COVAX Facility in October for ten million doses, and a deal with AstraZeneca in November will cover another ten million.
The government is now waiting to sign contracts next month with Moderna to secure vaccines for ten million people as well as with COVAX.
AstraZeneca's vaccines will be shipped in phases starting around February to March, followed by Janssen's in the second quarter of 2021 and Pfizer's in the third quarter.
The effectiveness of the vaccines differ, with AstraZeneca's showing an average 70 percent efficacy rate in the clinical phase, while those developed by Pfizer and Moderna showed 95 and 94-point-one percent efficacy rates, respectively.
2024-03-22
2024-03-25
2024-03-22
This website uses cookies and other technology to enhance quality of service. Continuous usage of the website will be considered as giving consent to the application of such technology and the policy of KBS. For further details >